Aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in China

The response rate (defined as the rate of reduction from baseline in the PANSS total score>30%) was also evaluated. The variables with P

Saved in:
Bibliographic Details
Published in:Chinese medical journal 2023-05, Vol.136 (9), p.1126-1128
Main Authors: Li, Qian, Su, Yun’ai, Liao, Xuemei, Fang, Maosheng, Gao, Jianliang, Xu, Jia, Duan, Mingjun, Yu, Haiying, Yang, Yang, Chen, Zhiyu, Liu, Jintong, Yan, Shaoxiao, Yao, Peifen, Li, Shuying, Wang, Changhong, Wu, Bin, Zhang, Congpei, Si, Tianmei
Format: Article
Language:English
Subjects:
Antipsychotic Agents - therapeutic use
Antipsychotics
Aripiprazole - therapeutic use
Benzodiazepines
China
Correspondence
Dopamine
Drug dosages
Humans
Metabolism
Psychotropic drugs
Regression analysis
Response rates
Risperidone
Schizophrenia
Schizophrenia - drug therapy
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c4978-220242148fdfdead80385e6442844c226c87c4b11ef458243a39e9958d12e4f33
container_end_page 1128
container_issue 9
container_start_page 1126
container_title Chinese medical journal
container_volume 136
creator Li, Qian
Su, Yun’ai
Liao, Xuemei
Fang, Maosheng
Gao, Jianliang
Xu, Jia
Duan, Mingjun
Yu, Haiying
Yang, Yang
Chen, Zhiyu
Liu, Jintong
Yan, Shaoxiao
Yao, Peifen
Li, Shuying
Wang, Changhong
Wu, Bin
Zhang, Congpei
Si, Tianmei
description The response rate (defined as the rate of reduction from baseline in the PANSS total score>30%) was also evaluated. The variables with P
doi_str_mv 10.1097/CM9.0000000000002551
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_880954475c53474e99487fb95e73db66</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_880954475c53474e99487fb95e73db66</doaj_id><sourcerecordid>2795357593</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4978-220242148fdfdead80385e6442844c226c87c4b11ef458243a39e9958d12e4f33</originalsourceid><addsrcrecordid>eNpdkstu1DAUhiMEokPhDRCKxIZNii_Hsc0GVSMulYrYwA7J8jgnjYdMHOyko_bpcTqltLUXlo7_8-k_l6J4TckJJVq-X3_TJ-TeYULQJ8WKCWCVqIE-LVaE13VVa62PihcpbW80sn5eHHFJKEhZr4pfp9GPfoz2OvRY-qGcOiyniHba4TCVoS2tmycscfQpNLgEkuv8dRi7iIO3H0pbZnVf7UPsmzJNc3O1YNadH-zL4llr-4Svbt_j4ufnTz_WX6vz71_O1qfnlQMtVcUYYcAoqLZpG7SNIlwJrAGYAnCM1U5JBxtKsQWhGHDLNWotVEMZQsv5cXF24DbBbs0Y_c7GKxOsNzeBEC-MjZN3PRqliBYAUjjBQULGgJLtRguUvNnUdWZ9PLDGebPDxuUuRNs_gD78GXxnLsKloYRlvxIy4d0tIYY_M6bJ7Hxy2Pd2wDAnw6QWXEihF-NvH0m3YY5D7pVhihEO2SzJKjioXAwpRWzv3FBill0weRfM413IaW_uV3KX9G_4_7n70E8Y0-9-3mM0XR7n1C08li2SKk-HE5FvlUNU8b--A7yn</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2820340950</pqid></control><display><type>article</type><title>Aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in China</title><source>LWW Online</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Li, Qian ; Su, Yun’ai ; Liao, Xuemei ; Fang, Maosheng ; Gao, Jianliang ; Xu, Jia ; Duan, Mingjun ; Yu, Haiying ; Yang, Yang ; Chen, Zhiyu ; Liu, Jintong ; Yan, Shaoxiao ; Yao, Peifen ; Li, Shuying ; Wang, Changhong ; Wu, Bin ; Zhang, Congpei ; Si, Tianmei</creator><creatorcontrib>Li, Qian ; Su, Yun’ai ; Liao, Xuemei ; Fang, Maosheng ; Gao, Jianliang ; Xu, Jia ; Duan, Mingjun ; Yu, Haiying ; Yang, Yang ; Chen, Zhiyu ; Liu, Jintong ; Yan, Shaoxiao ; Yao, Peifen ; Li, Shuying ; Wang, Changhong ; Wu, Bin ; Zhang, Congpei ; Si, Tianmei</creatorcontrib><description>The response rate (defined as the rate of reduction from baseline in the PANSS total score&gt;30%) was also evaluated. The variables with P &lt;0.2 in single factor analysis were included in multivariate logistic regression analysis. The response rate was 50.5% (311/616) for aripiprazole at the second week, and it rose to 84.4% (493/584) and 96.3% (523/543) at the fourth and eighth weeks, respectively. The proportions of patients with abnormal metabolic indicators including fasting blood glucose, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were decreased from baseline, but proportion of patients with abnormal triglyceride increased slightly [Figure 1A].</description><identifier>ISSN: 0366-6999</identifier><identifier>ISSN: 2542-5641</identifier><identifier>EISSN: 2542-5641</identifier><identifier>DOI: 10.1097/CM9.0000000000002551</identifier><identifier>PMID: 37014776</identifier><language>eng</language><publisher>China: Lippincott Williams &amp; Wilkins</publisher><subject>Antipsychotic Agents - therapeutic use ; Antipsychotics ; Aripiprazole - therapeutic use ; Benzodiazepines ; China ; Correspondence ; Dopamine ; Drug dosages ; Humans ; Metabolism ; Psychotropic drugs ; Regression analysis ; Response rates ; Risperidone ; Schizophrenia ; Schizophrenia - drug therapy ; Treatment Outcome</subject><ispartof>Chinese medical journal, 2023-05, Vol.136 (9), p.1126-1128</ispartof><rights>Lippincott Williams &amp; Wilkins</rights><rights>Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4978-220242148fdfdead80385e6442844c226c87c4b11ef458243a39e9958d12e4f33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228474/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2820340950?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37014776$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Qian</creatorcontrib><creatorcontrib>Su, Yun’ai</creatorcontrib><creatorcontrib>Liao, Xuemei</creatorcontrib><creatorcontrib>Fang, Maosheng</creatorcontrib><creatorcontrib>Gao, Jianliang</creatorcontrib><creatorcontrib>Xu, Jia</creatorcontrib><creatorcontrib>Duan, Mingjun</creatorcontrib><creatorcontrib>Yu, Haiying</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Chen, Zhiyu</creatorcontrib><creatorcontrib>Liu, Jintong</creatorcontrib><creatorcontrib>Yan, Shaoxiao</creatorcontrib><creatorcontrib>Yao, Peifen</creatorcontrib><creatorcontrib>Li, Shuying</creatorcontrib><creatorcontrib>Wang, Changhong</creatorcontrib><creatorcontrib>Wu, Bin</creatorcontrib><creatorcontrib>Zhang, Congpei</creatorcontrib><creatorcontrib>Si, Tianmei</creatorcontrib><title>Aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in China</title><title>Chinese medical journal</title><addtitle>Chin Med J (Engl)</addtitle><description>The response rate (defined as the rate of reduction from baseline in the PANSS total score&gt;30%) was also evaluated. The variables with P &lt;0.2 in single factor analysis were included in multivariate logistic regression analysis. The response rate was 50.5% (311/616) for aripiprazole at the second week, and it rose to 84.4% (493/584) and 96.3% (523/543) at the fourth and eighth weeks, respectively. The proportions of patients with abnormal metabolic indicators including fasting blood glucose, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were decreased from baseline, but proportion of patients with abnormal triglyceride increased slightly [Figure 1A].</description><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotics</subject><subject>Aripiprazole - therapeutic use</subject><subject>Benzodiazepines</subject><subject>China</subject><subject>Correspondence</subject><subject>Dopamine</subject><subject>Drug dosages</subject><subject>Humans</subject><subject>Metabolism</subject><subject>Psychotropic drugs</subject><subject>Regression analysis</subject><subject>Response rates</subject><subject>Risperidone</subject><subject>Schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Treatment Outcome</subject><issn>0366-6999</issn><issn>2542-5641</issn><issn>2542-5641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkstu1DAUhiMEokPhDRCKxIZNii_Hsc0GVSMulYrYwA7J8jgnjYdMHOyko_bpcTqltLUXlo7_8-k_l6J4TckJJVq-X3_TJ-TeYULQJ8WKCWCVqIE-LVaE13VVa62PihcpbW80sn5eHHFJKEhZr4pfp9GPfoz2OvRY-qGcOiyniHba4TCVoS2tmycscfQpNLgEkuv8dRi7iIO3H0pbZnVf7UPsmzJNc3O1YNadH-zL4llr-4Svbt_j4ufnTz_WX6vz71_O1qfnlQMtVcUYYcAoqLZpG7SNIlwJrAGYAnCM1U5JBxtKsQWhGHDLNWotVEMZQsv5cXF24DbBbs0Y_c7GKxOsNzeBEC-MjZN3PRqliBYAUjjBQULGgJLtRguUvNnUdWZ9PLDGebPDxuUuRNs_gD78GXxnLsKloYRlvxIy4d0tIYY_M6bJ7Hxy2Pd2wDAnw6QWXEihF-NvH0m3YY5D7pVhihEO2SzJKjioXAwpRWzv3FBill0weRfM413IaW_uV3KX9G_4_7n70E8Y0-9-3mM0XR7n1C08li2SKk-HE5FvlUNU8b--A7yn</recordid><startdate>20230505</startdate><enddate>20230505</enddate><creator>Li, Qian</creator><creator>Su, Yun’ai</creator><creator>Liao, Xuemei</creator><creator>Fang, Maosheng</creator><creator>Gao, Jianliang</creator><creator>Xu, Jia</creator><creator>Duan, Mingjun</creator><creator>Yu, Haiying</creator><creator>Yang, Yang</creator><creator>Chen, Zhiyu</creator><creator>Liu, Jintong</creator><creator>Yan, Shaoxiao</creator><creator>Yao, Peifen</creator><creator>Li, Shuying</creator><creator>Wang, Changhong</creator><creator>Wu, Bin</creator><creator>Zhang, Congpei</creator><creator>Si, Tianmei</creator><general>Lippincott Williams &amp; Wilkins</general><general>Lippincott Williams &amp; Wilkins Ovid Technologies</general><general>Wolters Kluwer</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230505</creationdate><title>Aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in China</title><author>Li, Qian ; Su, Yun’ai ; Liao, Xuemei ; Fang, Maosheng ; Gao, Jianliang ; Xu, Jia ; Duan, Mingjun ; Yu, Haiying ; Yang, Yang ; Chen, Zhiyu ; Liu, Jintong ; Yan, Shaoxiao ; Yao, Peifen ; Li, Shuying ; Wang, Changhong ; Wu, Bin ; Zhang, Congpei ; Si, Tianmei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4978-220242148fdfdead80385e6442844c226c87c4b11ef458243a39e9958d12e4f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotics</topic><topic>Aripiprazole - therapeutic use</topic><topic>Benzodiazepines</topic><topic>China</topic><topic>Correspondence</topic><topic>Dopamine</topic><topic>Drug dosages</topic><topic>Humans</topic><topic>Metabolism</topic><topic>Psychotropic drugs</topic><topic>Regression analysis</topic><topic>Response rates</topic><topic>Risperidone</topic><topic>Schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Qian</creatorcontrib><creatorcontrib>Su, Yun’ai</creatorcontrib><creatorcontrib>Liao, Xuemei</creatorcontrib><creatorcontrib>Fang, Maosheng</creatorcontrib><creatorcontrib>Gao, Jianliang</creatorcontrib><creatorcontrib>Xu, Jia</creatorcontrib><creatorcontrib>Duan, Mingjun</creatorcontrib><creatorcontrib>Yu, Haiying</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Chen, Zhiyu</creatorcontrib><creatorcontrib>Liu, Jintong</creatorcontrib><creatorcontrib>Yan, Shaoxiao</creatorcontrib><creatorcontrib>Yao, Peifen</creatorcontrib><creatorcontrib>Li, Shuying</creatorcontrib><creatorcontrib>Wang, Changhong</creatorcontrib><creatorcontrib>Wu, Bin</creatorcontrib><creatorcontrib>Zhang, Congpei</creatorcontrib><creatorcontrib>Si, Tianmei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Chinese medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Qian</au><au>Su, Yun’ai</au><au>Liao, Xuemei</au><au>Fang, Maosheng</au><au>Gao, Jianliang</au><au>Xu, Jia</au><au>Duan, Mingjun</au><au>Yu, Haiying</au><au>Yang, Yang</au><au>Chen, Zhiyu</au><au>Liu, Jintong</au><au>Yan, Shaoxiao</au><au>Yao, Peifen</au><au>Li, Shuying</au><au>Wang, Changhong</au><au>Wu, Bin</au><au>Zhang, Congpei</au><au>Si, Tianmei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in China</atitle><jtitle>Chinese medical journal</jtitle><addtitle>Chin Med J (Engl)</addtitle><date>2023-05-05</date><risdate>2023</risdate><volume>136</volume><issue>9</issue><spage>1126</spage><epage>1128</epage><pages>1126-1128</pages><issn>0366-6999</issn><issn>2542-5641</issn><eissn>2542-5641</eissn><abstract>The response rate (defined as the rate of reduction from baseline in the PANSS total score&gt;30%) was also evaluated. The variables with P &lt;0.2 in single factor analysis were included in multivariate logistic regression analysis. The response rate was 50.5% (311/616) for aripiprazole at the second week, and it rose to 84.4% (493/584) and 96.3% (523/543) at the fourth and eighth weeks, respectively. The proportions of patients with abnormal metabolic indicators including fasting blood glucose, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were decreased from baseline, but proportion of patients with abnormal triglyceride increased slightly [Figure 1A].</abstract><cop>China</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>37014776</pmid><doi>10.1097/CM9.0000000000002551</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0366-6999
ispartof Chinese medical journal, 2023-05, Vol.136 (9), p.1126-1128
issn 0366-6999
2542-5641
2542-5641
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_880954475c53474e99487fb95e73db66
source LWW Online; Publicly Available Content Database; PubMed Central
subjects Antipsychotic Agents - therapeutic use
Antipsychotics
Aripiprazole - therapeutic use
Benzodiazepines
China
Correspondence
Dopamine
Drug dosages
Humans
Metabolism
Psychotropic drugs
Regression analysis
Response rates
Risperidone
Schizophrenia
Schizophrenia - drug therapy
Treatment Outcome
title Aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in China
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T16%3A05%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aripiprazole%20in%20the%20treatment%20of%20acute%20episode%20of%20schizophrenia:%20a%20real-world%20study%20in%20China&rft.jtitle=Chinese%20medical%20journal&rft.au=Li,%20Qian&rft.date=2023-05-05&rft.volume=136&rft.issue=9&rft.spage=1126&rft.epage=1128&rft.pages=1126-1128&rft.issn=0366-6999&rft.eissn=2542-5641&rft_id=info:doi/10.1097/CM9.0000000000002551&rft_dat=%3Cproquest_doaj_%3E2795357593%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4978-220242148fdfdead80385e6442844c226c87c4b11ef458243a39e9958d12e4f33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2820340950&rft_id=info:pmid/37014776&rfr_iscdi=true